rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Protalix BioTherapeutics, Inc. (DE)

PLX · NYSE American

Health CareBiotechnologyAbove a falling average

PLX stood above a rising 150-day average in 25 of the last 52 weekly readings, and has been out of that trend for the last 3 weeks. It is 12.2% above that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Above a falling average
Weeks in an uptrend
out for 3
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$101K
Insider sales, 12 months
$314
Officials’ trades on record
0
Institutions holding
102 (+6)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 25 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$199KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months1
Sale orders, 12 months1
Buyers · sellers1 · 1

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders102+6 on the quarter
New · exited22 · 16
Reported value$34.0M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
BlackRock, Inc.added · filed 7 Aug 20264,046,650$9.4M+429,688+11.9%
RENAISSANCE TECHNOLOGIES LLCreduced · filed 13 Aug 20261,096,000$2.6M-128,800−10.5%
STATE STREET CORPadded · filed 7 Aug 2026983,582$2.3M+10,767+1.1%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026979,995$2.3M+114,697+13.3%
NORTHERN TRUST CORPadded · filed 13 Aug 2026922,340$2.1M+36,892+4.2%
VANGUARD PORTFOLIO MANAGEMENT LLCadded · filed 13 Aug 2026510,639$1.2M+78,154+18.1%
Stratos Wealth Partners, LTD.unchanged · filed 11 Aug 2026500,000$1.2M00.0%
DIMENSIONAL FUND ADVISORS LPadded · filed 11 Aug 2026493,424$1.1M+196,581+66.2%
GOLDMAN SACHS GROUP INCadded · filed 14 Aug 2026475,922$1.1M+224,577+89.4%
MARSHALL WACE, LLPnew · filed 13 Aug 2026452,757$1.1M+452,757
31 Mar 2023 – 30 Jun 2026
296499Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Aharon Schwartz Company insiderDirector · last 3 Sep 20263 · 0
Amos Bar-Shalev Company insiderDirector · last 3 Sep 20261 · 1
Christian Elze Company insiderDirector · last 3 Sep 20260 · 0
Dror Bashan Company insiderPRESIDENT AND CEO · last 3 Sep 20263 · 0
Eliot Forster Company insiderDirector · last 3 Sep 20260 · 0
Gwen A. Melincoff Company insiderDirector · last 3 Sep 20260 · 0
Pol F. Boudes Company insiderDirector · last 3 Sep 20260 · 0
Yaron Naos Company insiderSr. VP & COO · last 3 Sep 20260 · 0
Zvi Shmuel Ben Company insiderDirector · last 3 Sep 20260 · 0
Eyal Rubin Company insiderSr. VP and CFO · last 23 Sep 20240 · 0
Yael Hayon Company insiderVP, Research & Development · last 15 Aug 20230 · 0
Zeev Bronfeld Company insiderDirector · last 7 Sep 20220 · 1

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202548.8%
Operating profit marginFY 2025 · to 31 Dec 2025-10.4%
Free cash flow marginFY 2025 · to 31 Dec 2025-25.8%
Return on capital employedFY 2025 · to 31 Dec 2025-9.9%
Research spendFY 2025 · to 31 Dec 202537.1%
Share count trendFY 2025 · to 1 Mar 20260.2%
Cash and equivalentsFY 2025 · to 31 Dec 2025$14.7M
Free cash flowFY 2025 · to 31 Dec 2025−$13.6M

Analyst forecasts

No analyst forecasts yet.